International Journal of Molecular Sciences (Nov 2021)

<i>CRB1</i>-Related Retinal Dystrophies in a Cohort of 50 Patients: A Reappraisal in the Light of Specific Müller Cell and Photoreceptor <i>CRB1</i> Isoforms

  • Kévin Mairot,
  • Vasily Smirnov,
  • Béatrice Bocquet,
  • Gilles Labesse,
  • Carl Arndt,
  • Sabine Defoort-Dhellemmes,
  • Xavier Zanlonghi,
  • Dalil Hamroun,
  • Danièle Denis,
  • Marie-Christine Picot,
  • Thierry David,
  • Olivier Grunewald,
  • Mako Pégart,
  • Hélèna Huguet,
  • Anne-Françoise Roux,
  • Vasiliki Kalatzis,
  • Claire-Marie Dhaenens,
  • Isabelle Meunier

DOI
https://doi.org/10.3390/ijms222312642
Journal volume & issue
Vol. 22, no. 23
p. 12642

Abstract

Read online

Pathogenic variants in CRB1 lead to diverse recessive retinal disorders from severe Leber congenital amaurosis to isolated macular dystrophy. Until recently, no clear phenotype-genotype correlation and no appropriate mouse models existed. Herein, we reappraise the phenotype-genotype correlation of 50 patients with regards to the recently identified CRB1 isoforms: a canonical long isoform A localized in Müller cells (12 exons) and a short isoform B predominant in photoreceptors (7 exons). Twenty-eight patients with early onset retinal dystrophy (EORD) consistently had a severe Müller impairment, with variable impact on the photoreceptors, regardless of isoform B expression. Among them, two patients expressing wild type isoform B carried one variant in exon 12, which specifically damaged intracellular protein interactions in Müller cells. Thirteen retinitis pigmentosa patients had mainly missense variants in laminin G-like domains and expressed at least 50% of isoform A. Eight patients with the c.498_506del variant had macular dystrophy. In one family homozygous for the c.1562C>T variant, the brother had EORD and the sister macular dystrophy. In contrast with the mouse model, these data highlight the key role of Müller cells in the severity of CRB1-related dystrophies in humans, which should be taken into consideration for future clinical trials.

Keywords